Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time‐varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure‐response relationship for CZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Vande Casteele, N., Feagan, B. G., Vermeire, S., Yassine, M., Coarse, J., Kosutic, G., Sandborn, W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Certolizumab in Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765392/
https://www.ncbi.nlm.nih.gov/pubmed/29159893
http://dx.doi.org/10.1111/apt.14421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765392/
https://www.ncbi.nlm.nih.gov/pubmed/29159893
http://dx.doi.org/10.1111/apt.14421

Ejemplares similares